Search results for "DELE"

showing 10 items of 631 documents

De novo 15q21.1q21.2 deletion identified through FBN1 MLPA and refined by 244K array-CGH in a female teenager with incomplete Marfan syndrome

2010

International audience; Interstitial deletions involving the 15q21.1 band are very rare. Only 4 of these cases have been studied using molecular cytogenetic techniques in order to confirm the deletion of the whole FBN1 gene. The presence of clinical features of the Marfan syndrome (MFS) spectrum associated with mental retardation has been described in only 2/4 patients. Here we report on a 16-year-old female referred for suspicion of MFS (positive thumb and wrist sign, scoliosis, joint hyperlaxity, high-arched palate with dental crowding, dysmorphism, mitral insufficiency with dystrophic valve, striae). She had therefore 3 minor criteria according to the Ghent nosology. She also had speech …

AdultMalemusculoskeletal diseasesProbandMarfan syndromecongenital hereditary and neonatal diseases and abnormalitiesAdolescent[SDV]Life Sciences [q-bio]Fibrillin-1BiologyFibrillinsBioinformaticsPolymerase Chain ReactionMarfan SyndromeLoss of heterozygosity03 medical and health sciencesTransforming Growth Factor betaIntellectual DisabilityGeneticsmedicineHumansMultiplex ligation-dependent probe amplificationAlleleChildGeneIn Situ Hybridization FluorescenceGenetics (clinical)Oligonucleotide Array Sequence AnalysisSequence Deletion030304 developmental biologyGeneticsChromosomes Human Pair 15Comparative Genomic Hybridization0303 health sciencesMicrofilament Proteins030305 genetics & heredityGeneral Medicinemedicine.diseasePedigree3. Good healthPhenotypeMutationMicrosatelliteFemaleDNA ProbesHaploinsufficiencyMicrosatellite RepeatsEuropean Journal of Medical Genetics
researchProduct

Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene

1995

We report two novel polymorphisms and a rare deletion variant in the human dopaine D4 receptor gene. The two polymorphisms are characterized by single base pair substitutions, namely a G-->C transversion changing codon 11 from GGG (encoding Gly) to CGG (encoding Arg) and a C-->T transition in position -11 upstream from the start codon. The Arg11 variant occurs at a frequency of about 1% and the C-->T transition at a frequency of about 7% in German control subjects (n = 148). Allele frequencies observed in patients suffering from schizophrenia (n = 256) and bipolar affective disorder (n = 99) were similar. The deletion variant is characterized by a 21 bp deletion affecting codons 36 to 42 co…

AdultObsessive-Compulsive DisorderBipolar DisorderMolecular Sequence DataBiologymedicine.disease_causePolymerase Chain ReactionGene FrequencyStart codonReference ValuesLeukocytesGeneticsmedicineHumansPoint MutationAmino Acid SequenceAge of OnsetCodonTransversionGeneAllele frequencyBiological PsychiatryGenetics (clinical)DNA PrimersRepetitive Sequences Nucleic AcidSequence DeletionGeneticsMutationBase SequenceTransition (genetics)Receptors Dopamine D2Receptors Dopamine D4Genetic VariationDNAExonsMiddle Agedmedicine.diseasePsychiatry and Mental healthTransmembrane domainSchizophreniaSchizophreniaPanic DisorderPolymorphism Restriction Fragment Length
researchProduct

Deletion of Chromosome 11q Predicts Response to Anthracycline-Based Chemotherapy in Early Breast Cancer

2007

Abstract Despite the recent consensus on the eligibility of adjuvant systemic therapy in patients with lymph node–negative breast cancer (NNBC) based on clinicopathologic criteria, specific biological markers are needed to predict sensitivity to the different available therapeutic options. We examined the feasibility of developing a genomic predictor of chemotherapy response and recurrence risk in 185 patients with NNBC using assembled arrays containing 2,460 bacterial artificial chromosome clones for scanning the genome for DNA copy number changes. After surgery, 90 patients received anthracycline-based chemotherapy, whereas 95 did not. Tamoxifen was administered to patients with hormone r…

AdultOncologyCancer Researchmedicine.medical_specialtyPathologyAnthracyclinemedicine.medical_treatmentGene DosageBreast NeoplasmsBiologyGene dosageBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesGenetic Predisposition to DiseaseIn Situ Hybridization FluorescenceBacterial artificial chromosomeChemotherapyChromosomes Human Pair 11Nucleic Acid HybridizationGenomic signatureMiddle Agedmedicine.diseaseReceptors EstrogenOncologyLymphatic MetastasisPredictive value of testsFemaleChromosome DeletionNeoplasm Recurrence LocalReceptors ProgesteroneTamoxifenmedicine.drugCancer Research
researchProduct

Wilms' tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas

2012

Nephroblastoma (Wilms' tumor; WT) is the most common renal tumor of childhood. To date, several genetic abnormalities predisposing to WT have been identified in rare overgrowth syndromes. Among them, abnormal methylation of the 11p15 region, GPC3 and DIS3L2 mutations, which are responsible for Beckwith-Wiedemann, Simpson-Golabi-Behmel and Perlman syndromes, respectively. However, the underlying cause of WT remains unknown in the majority of cases. We report three unrelated patients who presented with WT in addition to a constitutional 9q22.3 microdeletion and dysmorphic/overgrowth syndrome. The size of the deletions was variable (ie, from 1.7 to 8.9 Mb) but invariably encompassed the PTCH1 …

AdultPatched Receptorsmedicine.medical_specialtyPathologyPTCH1AdolescentNonsense mutationCNVShort ReportReceptors Cell SurfaceBiologymedicine.disease_causeWilms’ tumorWilms TumorFetal MacrosomiaSettore MED/38 - Pediatria Generale E SpecialisticaPregnancyInternal medicineGeneticsmedicineHumansPerlman syndromeChildovergrowthGenetics (clinical)MutationComparative Genomic HybridizationWilms' tumorPTCH1 GeneMicrodeletion syndromeFANCC nephroblastomamedicine.diseaseKidney NeoplasmsPatched-1 ReceptorEndocrinologyPTCH1Settore MED/03 - Genetica MedicaOvergrowth syndromeMutationFemaleChromosome DeletionChromosomes Human Pair 9Comparative genomic hybridization
researchProduct

Liberaali välttämättömyys ja paljaan elämän politiikka

2010

Agamben GiorgiokontrolliFoucault MichelDeleuze Gillesvälttämättömyysbiopolitiikkahyvä elämäpoikkeustila
researchProduct

CCR5 Receptor: Biologic and Genetic Implications in Age-Related Diseases

2007

The CC chemokine receptor 5 (CCR5) is a member of CC-chemokine receptor family. CCR5 has the characteristic structure of a seven transmembrane G protein-coupled receptor (GPCR), which regulates trafficking and effector functions of memory/effector Th1 cells, macrophages, NK cells, and immature dendritic cells. CCR5 and its ligands are important molecules in viral pathogenesis. CCR5 represents the co-receptor for macrophage (M) and dual (T cell and M)-tropic immunodeficiency viruses. Recent evidence has also demonstrated the role of CCR5 in a variety of human diseases, ranging from infectious and inflammatory diseases to cancer. In this article, we describe the involvement of CCR5 in two age…

AgingChemokineReceptors CCR5Chemokine receptor CCR5virusesT cellViral pathogenesisDiseaseLigandsModels BiologicalGeneral Biochemistry Genetics and Molecular BiologyHistory and Philosophy of Sciencecardiovascular diseaseAlzheimer DiseasemedicineHumansMacrophageSettore MED/04 - Patologia GeneraleInflammationGenomebiologyEffectorMacrophagesGeneral Neurosciencevirus diseasesDendritic CellsAtherosclerosisKiller Cells Naturalmedicine.anatomical_structureCardiovascular DiseasesImmunologybiology.proteinMicrogliaCC chemokine receptorsAlzheimer’s diseaseCCR5Gene DeletionAnnals of the New York Academy of Sciences
researchProduct

Wine yeast sirtuins and Gcn5p control aging and metabolism in a natural growth medium.

2012

Grape juice fermentation by wine yeast is an interesting model to understand aging under conditions closer to those in nature. Grape juice is rich in sugars and, unlike laboratory conditions, the limiting factor for yeast growth is nitrogen. We tested the effect of deleting sirtuins and several acetyltransferases to find that the role of many of these proteins during grape juice fermentation is the opposite to that under standard laboratory aging conditions using synthetic complete media. For instance, . SIR2 deletion extends maximum chronological lifespan in wine yeasts grown under laboratory conditions, but shortens it in winemaking. Deletions of sirtuin . HST2 and acetyltransferase . GCN…

AgingSaccharomyces cerevisiae ProteinsNitrogenSaccharomyces cerevisiaeWineSaccharomyces cerevisiaeSirtuin 2AutophagySilent Information Regulator Proteins Saccharomyces cerevisiaeWinemakingAcetic AcidHistone AcetyltransferasesFermentation in winemakingWinebiologyfood and beveragesAldehyde Dehydrogenasebiology.organism_classificationYeastCulture MediaYeast in winemakingBiochemistrySirtuinFermentationbiology.proteinFermentationGene DeletionDevelopmental BiologyMechanisms of ageing and development
researchProduct

Mitä mieltä, professorit?

2006

25 vuoden ikään ehtinyt Aikuiskasvatus kysyi kaikilta aikuiskasvatuksen professoreiltamme heidän näkemyksiään neljässä asiassa. Kaikkiin ei tarvinnut vastata. Tällaista kysyttiin ja näin vastasivat Yrjö Engeström ja Reijo Miettinen Helsingin yliopistosta, Anneli Eteläpelto Jyväskylän yliopistosta, Jukka Tuomisto ja Juha Suoranta Tampereen yliopistosta, Risto Rinne Turun yliopistosta, Kari E. Nurmi Lapin yliopistosta sekä vt:nä virkaa hoitava Leena Ahteenmäki-Pelkonen Joensuun yliopistosta. Vastausjärjestys on arvottu.

Ahteenmäki-Pelkonen LeenaEngeström Yrjökasvatustieteilijät [http://www.yso.fi/onto/yso/p20573]Rinne RistoMiettinen ReijoGeneral MedicineGeneral Chemistrytiede [http://www.yso.fi/onto/yso/p2240]Eteläpelto Annelitiedelehdet [http://www.yso.fi/onto/yso/p10315]Nurmi Kari E.Tuomisto JukkaSuoranta Juhatutkimus [http://www.yso.fi/onto/yso/p183]aikuiskoulutus [http://www.yso.fi/onto/yso/p300][Aikuiskasvatus]aikuiskasvatus [http://www.yso.fi/onto/yso/p10754]professorit [http://www.yso.fi/onto/yso/p17044]Aikuiskasvatus
researchProduct

Mujer, poder político y democracia paritaria. “Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. 2 parte.

2014

Mujer, poder político y democracia paritaria. “Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. 2 parte. En esta segunda parte se recogen las mujeres que han formado parte de la Administración Local (alcaldesas, diputadas provinciales y FVMP), en los sindicatos, asi como en otras instituciones: Consell Valencià de Cultura, Consejo de Radiotelevisión Valenciana, Sindicatura de Agravios, Academia Valenciana de la Lengua, universidades, direcciones de partidos políticos, y otras organizaciones de la Comunidad Valenciana. “Mujer y representación política institucional en la Comunidad Valenciana. 1977-1995. Diputadas, ministras y cargos institucionales” es la …

Alcaldesas de la Comunidad Valenciana. Clementina Rodenas Villena. Rita Barberá Nolla. Josefa Mateu. Rosa Mazón. Carmen Gimeno. María Cabanes. Vicenta Bosch Palanca. Josefa Mateu. Violeta Rivera. Rosa Mengual. Empar Navarro i Prosper. Celeste García Estarlich. Mª. Dolores Botella Arbona. Carmen Martínez Ramírez. Gloria Isabel Calero Albal. Francisca R. Viciano Guillem. Teresa Parra Almiñana. Vicenta Tortosa Urrea. Rosa Maria Verdú Ramos. Mª. Milagrosa Martínez Navarro. Ana Noguera. María Ángeles Crespo Martínez. María Emma Iranzo Martín. Amparo Belmonte Burgos. María Ángeles Crespo Martínez. Lina Insa Rico. Teresa Ballester Artigues. Elena María Bastidas Bono. Mª. Elena Albentosa Ruso. María Rosa Verdú Alonso. María José Torres Amorós. María José García Herrero. Antonia Martínez Soler. Mª del Carmen Martínez Clemor. Enriqueta Seller Roca de Togores. Juliana González Maillo. Mercedes Alonso García. Mª de los Frutos Barceló La Torre. Luisa Pastor Lillo. Mª Antonieta Carratalá Aracil. María del Carmen Jiménez Egea. María Milagros Diego Martínez. Ana María Kringe Sánchez. Josefa Martín Bru. Luisa Pastor Lillo. María Gloria Pérez Martínez. María Teresa Sempere Juan. María Teresa Carbonell Bernabeu. María Loreto Martínez Ramos. Alicia Vázquez Fernández. Carmen García-Fuster y González-Alegre. Encarna Lerma Blasco. Francisca Gimeno Mocholi.Concha Martínez Romero. María A. Crespo Martínez. Gloria Arnandis Boix. Rosa Isabel Ribes Abel. Margarita Pin Arboledas. Nuria Espí de Navas. Purificación Martí Fenollosa. Asunción Quinzá Alegre. María Consuelo Orias Gonzalvo. Ascensión Figueres Górriz. María Remedios Vila Castelló. Mª Luisa Oliver Mallasén. Herminia Palomar Pérez. María Teresa Sidro. Carmina Martinavarro Moya. Consuelo Sanz Molés. Concepción Saenz Laín. Gobernadora civil de Castellón. Carmen Moya García delegada del Gobierno en la Comunidad Valenciana. Carmen Mas Rubio delegada del Gobierno en la Comunidad Valenciana. Pilar Brabo. Dulce Contreras Isabel Segura Maria Antonia García Benau. Cristina Santamaría Siurana. Isabel Morant. Adela Cortina. Neus Campillo. Trinidad Simó. Remedios Sánchez entre otras. Irene Abad Miró. María Francisca Abad García. Mari Luz Terradas. Amparo Caballer Cabo.Foro de Opinión. María Dolores Vilanova Alonso. Amparo Llop. María José Reyes. Mariló Pla. Cristina Piris. Victoria Prades. Mari Luz Marco. Julia Carles. Elisa Cabanes. Magarita Sanz Alonso. Ofelia Vila Hernández. Carme Morenilla i Talens. Rosa Mª Magdalena Rodríguez Pérez. Rosa Serrano Llácer. Síndic de Greuges de la Comunidad Valenciana. Julia Sevilla Merino. Emilia Caballero Álvarez. Ascensión Figueres Górriz. Carmen Barceló Torres. Verónica Cantó Doménech. Maria Soledad González Felip. Amàlia Alba Tarazona. Dones Progressistes. Susana Camarero Benitez. Macarena Montesinos. Marcela Miró Pérez. Pepa Chesa. Mª Josep Amigó. Teresa Blat. Lobby Europeo de Mujeres. Rosa Solbes. Inmaculada Serra Yoldi.:CIENCIA POLÍTICA [UNESCO]UNESCO::CIENCIA POLÍTICA
researchProduct

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

2013

Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. Methods Patients were randomized to receive deleobuvir 400 mg ( n=15) or 600 mg ( n=17) three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks. Interferon-free therapy was followed by response-guided faldaprevir plus pegylated interferon-α2a/ribavirin to week 24 or 48. Results…

Aminoisobutyric AcidsProline[SDV]Life Sciences [q-bio]610 Medicine & healthHepacivirusAntiviral AgentsDrug Administration SchedulePolyethylene GlycolsTherapy naive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHcv genotype 1LeucineRibavirinMedicine2736 Pharmacology (medical)Pharmacology (medical)Oral therapy030304 developmental biologyPharmacology0303 health sciencesbusiness.industryRibavirinDeleobuvirInterferon-alpha2725 Infectious DiseasesHepatitis C ChronicViral LoadVirologyRecombinant Proteins3. Good healthThiazolesInfectious DiseasesTreatment Outcome10219 Clinic for Gastroenterology and Hepatology3004 PharmacologychemistryAcrylatesFaldaprevirQuinolines030211 gastroenterology & hepatologyBenzimidazolesDrug Therapy CombinationbusinessOligopeptides
researchProduct